Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CODA vs CSBR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CODA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 9–1 Matrix Metrics)

CODA Overall Winner 6-Pillar Tally: CODA 4 – 1 CSBR (1 Tie) Matrix Metrics: CODA 9 – 1 CSBR

As of Nov 20, 2026, Coda Octopus Group, Inc. (CODA) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CODA carries a Unified Composite Score of 42.3/100 (HOLD) at $7.50 (13.3x Forward P/E, 20.1% operating margin), whereas CSBR carries 33.4/100 (SELL) at $4.34 (43.4x Forward P/E, -1.5% operating margin).

  • Technical & Structure Timing Caution: CODA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.0); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CODA vs CSBR
CODA NASDAQ Head-to-Head Winner
Coda Octopus Group, Inc. Common stock
Search, Detection, Navagation, Guidance, Aeronautical Sys
$7.50
-3.23% 1D
Market Cap $89.1M
TTM Revenue $29M
Forward P/E 13.3x
Beta / 30D Vol 1.49β · 56% Vol
Unified Composite Score
42.3 / 100 HOLD
Tech 25.0 Fund 50.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.5%), weak momentum, RSI 27
RSI-14: 27.0 · SMA20: $8.70 · SMA50: $9.74
CSBR NASDAQ
Champions Oncology, Inc.
Biological Products, (No Disgnostic Substances)
$4.34
-1.36% 1D
Market Cap $61.2M
TTM Revenue $61M
Forward P/E 43.4x
Beta / 30D Vol 0.36β · 24% Vol
Unified Composite Score
33.4 / 100 SELL
Tech 11.0 Fund 42.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.6%), weak momentum, RSI 29
RSI-14: 28.9 · SMA20: $4.72 · SMA50: $4.84

6-Pillar Scorecard Institutional Category Breakdown (CODA 4 – 1 CSBR)

Columns: Metric · CODA · CSBR
1. Valuation Multiples CODA
Forward P/E 13.3x 43.4x
Trailing P/E 17.9x 22.9x
PEG Ratio 3.81x N/M
EV / Revenue 2.1x 1.0x
2. Growth & Scale CODA
Revenue Growth (YoY) +9.2% +8.8%
Earnings Growth (YoY) +9.1% -61.1%
TTM Revenue (USD) $29M $61M
Market Cap $89.1M $61.2M
3. Profitability & Quality CODA
Gross Margin 66.1% 49.8%
Operating Margin 20.1% -1.5%
Net Profit Margin 17.6% -1.9%
Return on Equity (ROE) 8.4% -28.4%
4. Balance Sheet & Cash Flow CODA
Cash Generation (TTM) $5.9M $402,000 EBITDA
Cash Flow Margin 20.7% 0.7% EBITDA Mgn
Net Cash / Leverage $30M Net Cash $0.28 Book/Sh · -28.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CSBR
OpEx & R&D Intensity 46.0% of Rev ($13M) 51.3% of Rev ($31M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Aerospace & Defense Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CODA (9) vs CSBR (1)
Institutional Metric CODA CSBR Criterion Row Edge
Market Capitalization
Scale
$89.1M $61.2M Larger Scale CODA
Trailing P/E Ratio
Valuation
17.9x 22.9x Lower Multiple CODA
Forward P/E Ratio
Valuation
13.3x 43.4x Lower Multiple CODA
Revenue Growth (YoY)
Growth
+9.2% +8.8% Higher Growth CODA
Operating Margin (TTM)
Profitability
20.1% -1.5% Higher Margin CODA
Net Profit Margin
Profitability
17.6% -1.9% Higher Margin CODA
Return on Equity (ROE)
Capital Efficiency
8.4% -28.4% Higher ROE CODA
52-Week Range Position
Momentum
1% ($7–$17) 0% ($4–$8) Stronger Trend CODA
Beta / 30D Volatility
Risk Regime
1.49β · 56% Vol 0.36β · 24% Vol Lower Realized Risk CSBR
Unified Institutional Score
Composite Signal
42.3 / 100 (HOLD) 33.4 / 100 (SELL) Higher Composite CODA
Trailing 12M Revenue (USD)
Operating Scale
$29M $61M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
66.1% 49.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 2.1x EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$5.9M ($30M Net Cash) $402,000 EBITDA ($0.28 Book/Sh · -28.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CSBR +8.94 pp
CODA: -17.76% · CSBR: -8.82%
3M Horizon CSBR +12.32 pp
CODA: -25.0% · CSBR: -12.68%
6M Horizon CSBR +9.03 pp
CODA: -36.82% · CSBR: -27.79%
1Y Horizon CODA +28.89 pp
CODA: -7.75% · CSBR: -36.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CODA vs CSBR. Trailing 12-month operating profitability (CODA 20.1% vs CSBR -1.5%) and valuation multiples (CODA 13.3x vs CSBR 43.4x Forward P/E) are benchmarked directly in Pillar 4 below.

CODA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$29M
Gross Margin66.1%
Op. Margin20.1%
ROE / Fwd P/E8.4% · 13.3x
CSBR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$61M
Gross Margin49.8%
Op. Margin-1.5%
ROE / Fwd P/E-28.4% · 43.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CODA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CODA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CSBR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CSBR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CODA Moat Profile Scale & Operating Efficiency Moat
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $89.1M market capitalization and 20.1% operating margin.
OpEx & R&D Reinvestment 46.0% of Rev ($13M)
90D Engineering Disclosures 0 Published
CSBR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $61.2M market capitalization and -1.5% operating margin.
OpEx & R&D Reinvestment 51.3% of Rev ($31M)
90D Engineering Disclosures 0 Published

Investor FAQ CODA vs CSBR Key Questions & Quantitative Answers

As of Nov 20, 2026, Coda Octopus Group, Inc. (CODA) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CODA carries a Unified Composite Score of 42.3/100 (HOLD) at $7.50 (13.3x Forward P/E, 20.1% operating margin), whereas CSBR carries 33.4/100 (SELL) at $4.34 (43.4x Forward P/E, -1.5% operating margin). Technical & Structure Timing Caution: CODA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.0); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CODA leads the Growth & Scale pillar: CODA posts +9.2% YoY revenue growth and +9.1% YoY earnings growth on $29M TTM revenue (66.1% gross margin, 20.1% operating margin), compared with CSBR at +8.8% YoY revenue growth and -61.1% YoY earnings growth on $61M TTM revenue (49.8% gross margin, -1.5% operating margin). On trailing 12-month operating scale, CODA generates $29M in USD-normalized revenue versus $61M for CSBR. In operating R&D and SG&A reinvestment, CODA deploys 46.0% of Rev ($13M) (0 90-day corporate R&D disclosures) versus 51.3% of Rev ($31M) (0 disclosures) for CSBR.

CODA screens cheaper on headline valuation multiples. CODA trades at 13.3x Forward P/E, 17.9x Trailing P/E, 3.81x PEG, and 2.1x EV/Revenue (20.7% FCF margin), whereas CSBR trades at 43.4x Forward P/E, 22.9x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (0.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CODA (8.4% ROE) versus CSBR (-28.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CODA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 56% Vol realized risk). By comparison, CSBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.36β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.